{"id":68077,"date":"2026-11-10T06:51:56","date_gmt":"2026-11-10T01:21:56","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=68077"},"modified":"2026-11-10T06:52:02","modified_gmt":"2026-11-10T01:22:02","slug":"interactive-cardiology-mcqs-32-hypertension","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-32-hypertension\/","title":{"rendered":"Interactive Cardiology MCQs 32: Hypertension"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<!-- Cardiology MCQs Part 32 (Full 25 Questions - Hypertension) - WordPress Safe Custom HTML Block -->\n<script src=\"https:\/\/cdn.tailwindcss.com?plugins=forms,typography,aspect-ratio\"><\/script>\n<script>\n  tailwind.config = { corePlugins: { preflight: false } }\n<\/script>\n\n<div id=\"mcq32-quiz-wrapper\" class=\"font-sans bg-slate-950 text-slate-100 p-4 md:p-8 rounded-3xl max-w-4xl mx-auto shadow-2xl relative overflow-hidden my-8 border border-solid border-cyan-500\/20\" style=\"box-sizing: border-box;\">\n  \n  <div class=\"absolute top-0 left-0 w-full h-full pointer-events-none opacity-10 bg-[radial-gradient(ellipse_at_center,_var(--tw-gradient-stops))] from-cyan-500 via-blue-900 to-slate-950\"><\/div>\n  \n  <div class=\"relative text-center pb-6 border-b border-solid border-cyan-500\/25 mb-8\">\n    <div class=\"inline-block bg-gradient-to-r from-cyan-500 via-blue-600 to-indigo-600 text-white font-black text-xs md:text-sm px-4 py-1.5 rounded-full uppercase tracking-wider shadow-lg mb-3 animate-pulse\">\n      \u26a1 Advanced Cardiology Series &#8211; Part 32\n    <\/div>\n    <h1 class=\"text-3xl md:text-5xl font-extrabold tracking-tight text-transparent bg-clip-text bg-gradient-to-r from-cyan-300 via-blue-400 to-indigo-400 m-0\">\n      Interactive Cardiology MCQs #32\n    <\/h1>\n    <p class=\"text-sm md:text-lg text-slate-300 mt-2 max-w-2xl mx-auto font-medium\">\n      Post-Graduate Level Masterclass: Hypertension\n    <\/p>\n  <\/div>\n\n  <div class=\"sticky top-4 z-40 bg-slate-900\/90 backdrop-blur-md border-2 border-solid border-cyan-500\/40 rounded-2xl p-4 mb-8 shadow-xl flex flex-wrap items-center justify-between gap-4\">\n    <div class=\"flex items-center gap-3\">\n      <div class=\"text-3xl\">\ud83e\ude78<\/div>\n      <div>\n        <div class=\"text-[10px] uppercase font-extrabold tracking-widest text-cyan-300\">Live Scoreboard<\/div>\n        <div class=\"text-lg md:text-2xl font-black text-blue-300 flex items-center gap-1\">\n          <span id=\"mcq32-correct-count\">0<\/span><span class=\"text-slate-500 text-sm md:text-lg\">\/ 25 Correct<\/span>\n        <\/div>\n      <\/div>\n    <\/div>\n    <div class=\"flex items-center gap-2 bg-slate-950\/80 px-4 py-2 rounded-xl border border-solid border-slate-800\">\n      <span class=\"text-xs font-bold text-slate-400 uppercase tracking-wider\">Progress:<\/span>\n      <div class=\"w-24 md:w-36 bg-slate-800 h-3 rounded-full overflow-hidden\">\n        <div id=\"mcq32-progress-bar\" class=\"bg-gradient-to-r from-cyan-500 to-blue-500 h-full w-0 transition-all duration-300 rounded-full\"><\/div>\n      <\/div>\n      <span class=\"text-xs font-bold text-blue-300\"><span id=\"mcq32-answered-count\">0<\/span>\/25<\/span>\n    <\/div>\n  <\/div>\n\n  <div class=\"space-y-8 relative\">\n\n    <!-- Q1 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q1<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          The landmark SPRINT trial evaluated intensive versus standard blood pressure control. What was the primary finding regarding the intensive treatment target (systolic BP less than 120 mmHg) in non-diabetic adults at high cardiovascular risk?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Intensive BP control did not increase strokes; it actually trended toward reducing them.\">A) It significantly reduced myocardial infarctions but increased the incidence of hemorrhagic strokes.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The SPRINT trial demonstrated that targeting a systolic BP of less than 120 mmHg (intensive) compared to less than 140 mmHg (standard) resulted in a significantly lower rate of fatal and nonfatal major cardiovascular events and death from any cause, although with higher rates of some adverse events like hypotension, syncope, and AKI. Reference: SPRINT Research Group, NEJM 2015.\">B) It significantly reduced the composite outcome of myocardial infarction, acute coronary syndromes, stroke, heart failure, or cardiovascular death.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"The trial was actually stopped early (at 3.26 years instead of 5) due to the overwhelming benefit seen in the intensive treatment group.\">C) It showed no significant difference in cardiovascular outcomes, leading to the trial continuing for its full intended duration.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"While renal adverse events (like AKI) were higher in the intensive group, the cardiovascular benefits were highly significant.\">D) It significantly increased the progression to end-stage renal disease without improving cardiovascular mortality.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q2 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q2<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          According to the PATHWAY-2 trial, which pharmacological agent is the most effective add-on (fourth-line) therapy for patients with resistant hypertension already taking an ACE inhibitor\/ARB, calcium channel blocker, and a thiazide-like diuretic?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Bisoprolol (a beta-blocker) was less effective than spironolactone in the PATHWAY-2 trial.\">A) Bisoprolol.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Doxazosin (an alpha-blocker) was evaluated in PATHWAY-2 but was inferior to spironolactone for BP reduction.\">B) Doxazosin.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The PATHWAY-2 trial established Spironolactone (a mineralocorticoid receptor antagonist) as the most effective fourth-line therapy for resistant hypertension, proving superior to bisoprolol, doxazosin, and placebo. This suggests that sodium retention is a primary driver of resistant hypertension. Reference: PATHWAY-2 Trial, The Lancet 2015.\">C) Spironolactone.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Clonidine is a centrally acting alpha-2 agonist used for refractory cases, but it was not the superior drug identified in the PATHWAY-2 trial.\">D) Clonidine.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q3 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q3<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          When screening for Primary Aldosteronism in a hypertensive patient, the Aldosterone-to-Renin Ratio (ARR) is the recommended first step. Which pattern of plasma aldosterone concentration (PAC) and plasma renin activity (PRA) strongly indicates Primary Aldosteronism?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Primary Aldosteronism is characterized by autonomous, unregulated production of aldosterone by the adrenal glands, which suppresses renin via negative feedback. Therefore, the classic screening finding is a high PAC coupled with a suppressed (low) PRA, yielding a high Aldosterone-to-Renin Ratio. Reference: Endocrine Society Clinical Practice Guidelines.\">A) High Plasma Aldosterone Concentration and low (suppressed) Plasma Renin Activity.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"High PAC and high PRA indicates Secondary Hyperaldosteronism (e.g., from renal artery stenosis, heart failure, or diuretic use).\">B) High Plasma Aldosterone Concentration and high Plasma Renin Activity.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Low PAC and low PRA suggests conditions like Liddle syndrome, congenital adrenal hyperplasia, or exogenous mineralocorticoid use.\">C) Low Plasma Aldosterone Concentration and low Plasma Renin Activity.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Low PAC and high PRA is seen in primary adrenal insufficiency (Addison's disease), which causes hypotension, not hypertension.\">D) Low Plasma Aldosterone Concentration and high Plasma Renin Activity.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q4 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q4<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          After a positive screening test for Primary Aldosteronism (high ARR), a confirmatory test must be performed. Which of the following is an accepted confirmatory test demonstrating autonomous aldosterone secretion?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"The overnight dexamethasone suppression test is used to screen for Cushing's syndrome (hypercortisolism), not primary aldosteronism.\">A) Overnight 1mg Dexamethasone suppression test.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Confirmatory testing for Primary Aldosteronism relies on demonstrating that aldosterone secretion is autonomous and cannot be suppressed by volume expansion. The Intravenous Saline Infusion Test (infusing 2 liters of 0.9% NaCl over 4 hours) is a standard confirmatory test. If post-infusion aldosterone remains elevated (greater than 10 ng\/dL), autonomous secretion is confirmed. Oral sodium loading or captopril challenge are alternatives. Reference: Endocrine Society Clinical Practice Guidelines.\">B) Intravenous Saline Infusion Test.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"The Cosyntropin (ACTH) stimulation test is used to diagnose adrenal insufficiency, not primary aldosteronism.\">C) Cosyntropin (ACTH) stimulation test.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Clonidine suppression testing is used in the diagnosis of pheochromocytoma, not primary aldosteronism.\">D) Clonidine suppression test.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q5 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q5<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A young patient presents with severe hypertension, hypokalemia, and metabolic alkalosis. Laboratory testing reveals LOW plasma renin activity AND LOW plasma aldosterone levels. What is the most likely genetic diagnosis?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Liddle Syndrome is an autosomal dominant condition characterized by a gain-of-function mutation in the epithelial sodium channels (ENaC) of the renal collecting tubules. This leads to unregulated sodium reabsorption (causing hypertension) and potassium\/hydrogen secretion (causing hypokalemia\/alkalosis). The volume expansion suppresses BOTH renin and aldosterone. Reference: Genetics of Secondary Hypertension.\">A) Liddle Syndrome.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Primary aldosteronism (Conn's syndrome) presents with HIGH aldosterone and LOW renin.\">B) Conn&#8217;s Syndrome.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Fibromuscular dysplasia causes renal artery stenosis, leading to secondary hyperaldosteronism, characterized by HIGH renin and HIGH aldosterone.\">C) Fibromuscular Dysplasia.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Gitelman syndrome causes salt wasting, leading to hypotension (or normotension), hypokalemia, and metabolic alkalosis.\">D) Gitelman Syndrome.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q6 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q6<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Why are ACE inhibitors and ARBs strictly contraindicated in patients with bilateral renal artery stenosis (or unilateral stenosis in a solitary kidney)?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"ACE inhibitors do not cause direct toxic necrosis; their effect is hemodynamic.\">A) They cause direct toxic acute tubular necrosis due to drug accumulation in the ischemic kidney.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"ACE inhibitors decrease aldosterone, which typically leads to potassium retention (hyperkalemia), not severe hypokalemia.\">B) They trigger severe, life-threatening hypokalemia by increasing distal tubular flow.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"In bilateral renal artery stenosis, renal perfusion is heavily dependent on Angiotensin II-mediated efferent arteriole vasoconstriction to maintain the Glomerular Filtration Rate (GFR). Administering an ACE inhibitor or ARB removes this efferent constriction, causing a precipitous drop in intraglomerular pressure and acute renal failure. Reference: ACC\/AHA Guidelines for the Management of Hypertension.\">C) They abolish Angiotensin II-mediated efferent arteriolar constriction, causing a precipitous drop in Glomerular Filtration Rate (GFR) and acute renal failure.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"ACE inhibitors prevent Angiotensin II formation; they do not cause a paradoxical renin surge that worsens hypertension (in fact, they are very effective at lowering BP in unilateral RAS).\">D) They induce a paradoxical surge in renin release that severely exacerbates the hypertension.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q7 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q7<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A 28-year-old female presents with new-onset, severe hypertension. Renal angiography reveals a &#8220;string of beads&#8221; appearance in the mid-to-distal right renal artery. What is the most likely diagnosis?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Atherosclerotic renal artery stenosis typically occurs in older patients and affects the ostium (proximal third) of the renal artery, not the mid-to-distal portion, and does not have a beaded appearance.\">A) Atherosclerotic Renal Artery Stenosis.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Fibromuscular Dysplasia (FMD) is a non-atherosclerotic, non-inflammatory vascular disease that most commonly affects young to middle-aged women. The medial fibroplasia subtype typically affects the mid-to-distal renal arteries and yields a classic 'string of beads' appearance on angiography. It is a major cause of secondary hypertension in this demographic. Reference: ACC\/AHA Peripheral Artery Disease Guidelines.\">B) Fibromuscular Dysplasia (FMD).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Polyarteritis Nodosa can cause renal microaneurysms, but the classic mid-distal 'string of beads' in a young female is the hallmark of FMD.\">C) Polyarteritis Nodosa.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Takayasu arteritis is a large-vessel vasculitis that causes smooth, tapered stenosis or occlusion, usually affecting the aorta and its main branches, not a beaded appearance.\">D) Takayasu Arteritis.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q8 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q8<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          In the preoperative pharmacological preparation of a patient with a confirmed Pheochromocytoma, what is the mandatory sequence of autonomic receptor blockade?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Starting with a beta-blocker leaves alpha-receptors unopposed, precipitating a hypertensive crisis.\">A) Beta-blockade must be initiated first to control tachycardia, followed by alpha-blockade.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Patients with pheochromocytoma must absolutely undergo Alpha-blockade first (typically with phenoxybenzamine or doxazosin) to ensure adequate vasodilation. Only AFTER adequate alpha-blockade is achieved should Beta-blockers be added (to control reflex tachycardia). Administering a beta-blocker first removes beta-2 mediated vasodilation, leaving alpha-1 mediated vasoconstriction unopposed, triggering a lethal hypertensive crisis. Reference: Endocrine Society Guidelines for Pheochromocytoma.\">B) Alpha-blockade must be initiated first, followed by beta-blockade only after adequate alpha-blockade is established.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Simultaneous initiation can still lead to transient unopposed alpha activity if the drugs have different onsets of action. Alpha first is mandatory.\">C) Alpha and Beta blockade must be initiated simultaneously to prevent reflex tachycardia.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Calcium channel blockers can be used as an adjunct, but the standard protocol demands alpha then beta blockade.\">D) Calcium channel blockers must be initiated first, followed by simultaneous alpha and beta blockade.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q9 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q9<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A 15-year-old male is found to have severe hypertension in his upper extremities but weak, delayed femoral pulses. A chest X-ray reveals bilateral inferior rib notching. What is the mechanism behind this radiographic finding?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Increased venous pressure in the azygous system does not cause classic rib notching.\">A) Increased central venous pressure dilating the azygous vein, causing pressure erosion of the ribs.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"While ventricular hypertrophy occurs, it does not mechanically erode the ribs.\">B) Severe left ventricular hypertrophy mechanically compressing the lower ribs during systole.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The patient has Coarctation of the Aorta. To bypass the severe aortic narrowing, collateral circulation develops. The intercostal arteries (which connect the internal mammary arteries to the descending aorta) become massively dilated and tortuous. These enlarged, pulsatile intercostal arteries run along the inferior margin of the ribs, causing pressure erosion and the classic radiographic sign of 'inferior rib notching'. Reference: AHA\/ACC Guidelines for Adults with Congenital Heart Disease.\">C) Dilation and tortuosity of the intercostal arteries acting as collateral circulation to bypass the aortic obstruction.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Osteogenesis imperfecta causes fragile bones, but rib notching is a specific vascular erosion sign.\">D) A concurrent collagen synthesis defect leading to spontaneous rib micro-fractures.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q10 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q10<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient presents to the ER with &#8216;tearing&#8217; chest pain radiating to the back. A CT angiogram confirms an acute Stanford Type B Aortic Dissection. His blood pressure is 220\/120 mmHg. What is the immediate target for blood pressure management?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Decreasing BP by only 25% is the standard for most hypertensive emergencies, but aortic dissection is the critical exception requiring much more aggressive lowering.\">A) Decrease the mean arterial pressure by no more than 25 percent within the first hour to prevent cerebral ischemia.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Acute Aortic Dissection is a unique hypertensive emergency. The guidelines mandate extremely aggressive and rapid BP reduction. The goal is to reduce the systolic blood pressure to less than 120 mmHg (often between 100-120 mmHg) and heart rate to less than 60 bpm within 20 minutes to minimize aortic wall shear stress (dP\/dt). This is usually achieved with an IV beta-blocker (like Esmolol) followed by a vasodilator (like Nitroprusside). Reference: AHA\/ACC Guidelines for the Diagnosis and Management of Patients with Thoracic Aortic Disease.\">B) Rapidly reduce the systolic blood pressure to less than 120 mmHg within 20 minutes.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Lowering BP strictly to 160\/100 is inadequate and leaves the aortic wall subjected to high tearing forces.\">C) Gradually reduce the systolic blood pressure to 160\/100 mmHg over the first 24 hours.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Permissive hypertension is used in acute ischemic stroke, not aortic dissection where high pressure is lethal.\">D) Maintain permissive hypertension to ensure adequate spinal cord and renal perfusion.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q11 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q11<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          In a patient presenting with an Acute Ischemic Stroke who is NOT a candidate for thrombolytic therapy (tPA) or mechanical thrombectomy, at what blood pressure threshold should pharmacological antihypertensive treatment be initiated?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"160\/100 mmHg is a target for general long-term control, but acute stroke requires permissive hypertension to maintain cerebral perfusion.\">A) Greater than 160\/100 mmHg.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"185\/110 mmHg is the threshold if the patient IS receiving thrombolysis (tPA).\">B) Greater than 185\/110 mmHg.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"In the acute phase of an ischemic stroke, 'permissive hypertension' is allowed to maintain collateral perfusion to the ischemic penumbra. For patients NOT receiving reperfusion therapy (tPA or thrombectomy), antihypertensive medications should be withheld unless the blood pressure is extreme: strictly defined as greater than or equal to 220\/120 mmHg, or if there is another concomitant emergency (e.g., aortic dissection). Reference: AHA\/ASA Guidelines for the Early Management of Patients with Acute Ischemic Stroke.\">C) Greater than or equal to 220\/120 mmHg.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"140\/90 mmHg is a standard outpatient goal, but aggressive lowering acutely will worsen the stroke by starving the penumbra.\">D) Greater than 140\/90 mmHg.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q12 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q12<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Which of the following antihypertensive medications is strictly CONTRAINDICATED in pregnancy due to known severe teratogenicity, including fetal renal dysgenesis and oligohydramnios?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Labetalol is one of the first-line agents for hypertension in pregnancy.\">A) Labetalol.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Methyldopa has a long safety record and is a standard treatment for chronic hypertension in pregnancy.\">B) Methyldopa.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Nifedipine (extended-release) is a safe and effective oral calcium channel blocker used in pregnancy.\">C) Nifedipine.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"ACE inhibitors (like Lisinopril), ARBs, and Direct Renin Inhibitors are strictly contraindicated in all trimesters of pregnancy. They interfere with fetal renin-angiotensin system development, leading to fetal renal dysgenesis, profound oligohydramnios, pulmonary hypoplasia, and skull ossification defects. Reference: ACOG Practice Bulletin on Chronic Hypertension in Pregnancy.\">D) ACE Inhibitors (e.g., Lisinopril).<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q13 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q13<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient receiving a prolonged, high-dose intravenous infusion of Sodium Nitroprusside for a hypertensive emergency develops altered mental status, lactic acidosis, and an almond-like breath odor. What is the appropriate specific antidote?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Flumazenil is the antidote for benzodiazepine overdose, not nitroprusside toxicity.\">A) Flumazenil.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Sodium nitroprusside metabolism produces nitric oxide (the vasodilator) and cyanide. Prolonged or high-dose infusions, especially in patients with renal or hepatic impairment, can lead to severe Cyanide Toxicity (lactic acidosis, confusion, seizures, almond breath). The specific treatment includes stopping the infusion and administering Sodium Thiosulfate (which provides a sulfur donor for the enzyme rhodanese to convert cyanide to non-toxic thiocyanate), Hydroxocobalamin, or Sodium Nitrite. Reference: ACC\/AHA Hypertension Guidelines.\">B) Sodium Thiosulfate.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"N-acetylcysteine is the antidote for acetaminophen (paracetamol) overdose and a mucolytic, not for cyanide toxicity.\">C) N-acetylcysteine.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Glucagon is the antidote for severe beta-blocker or calcium channel blocker overdose.\">D) Glucagon.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q14 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q14<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          What is the clinical definition of &#8216;Masked Hypertension&#8217; as identified by Ambulatory Blood Pressure Monitoring (ABPM)?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This defines 'White Coat Hypertension'.\">A) Blood pressure is elevated in the clinical setting but normal on 24-hour ABPM.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Masked Hypertension is the dangerous inverse of white coat hypertension. It is defined as a normal blood pressure when measured in the clinic (office), but consistently elevated blood pressure readings outside the clinic, verified by 24-hour Ambulatory Blood Pressure Monitoring (ABPM) or Home BP Monitoring. These patients carry a cardiovascular risk similar to those with sustained hypertension. Reference: ACC\/AHA and ESC Guidelines on Hypertension.\">B) Blood pressure is normal in the clinical setting but elevated on 24-hour ABPM.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes sustained, true hypertension.\">C) Blood pressure is elevated both in the clinical setting and on 24-hour ABPM.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes isolated nocturnal hypertension, which is a subtype of non-dipping, but not the broad definition of masked hypertension.\">D) Blood pressure is normal during waking hours but fails to dip more than 10 percent during sleep.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q15 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q15<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Based on the ALLHAT trial and current ACC\/AHA guidelines, which two drug classes are the recommended initial monotherapy options for managing uncomplicated primary hypertension in Black patients?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"ACE inhibitors are significantly less effective as monotherapy in the Black population, which tends to have a low-renin hypertensive profile.\">A) ACE Inhibitors and Beta-blockers.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"ARBs share the same diminished monotherapy efficacy profile in this demographic as ACE inhibitors.\">B) ARBs and Beta-blockers.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The ALLHAT trial and subsequent guidelines clearly established that in Black adults with uncomplicated hypertension (without heart failure or chronic kidney disease), initial monotherapy should be either a Thiazide-type diuretic (e.g., chlorthalidone) or a Calcium Channel Blocker (e.g., amlodipine). This population tends to have low-renin, salt-sensitive hypertension, making RAAS inhibitors less effective as initial single agents. Reference: ACC\/AHA Guidelines for High Blood Pressure.\">C) Thiazide-type Diuretics and Calcium Channel Blockers.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Loop diuretics are reserved for volume overload states (like heart failure\/CKD), not routine uncomplicated hypertension.\">D) Loop Diuretics and Alpha-blockers.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q16 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q16<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Thiazide diuretics (e.g., Hydrochlorothiazide, Chlorthalidone) have a specific metabolic side effect profile that can be remembered by the mnemonic &#8216;HyperGLUC&#8217;. Which of the following metabolic disturbances is NOT typically caused by thiazides?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Hyperglycemia is a known side effect (the 'G' in HyperGLUC).\">A) Hyperglycemia.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Hyperuricemia (which can trigger gout) is a classic side effect (the 'U' in HyperGLUC).\">B) Hyperuricemia.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Thiazide diuretics cause HYPERcalcemia (the 'C' in HyperGLUC), because they enhance calcium reabsorption in the distal convoluted tubule. They do NOT cause hypocalcemia. Conversely, Loop diuretics (like furosemide) cause calcium excretion and can lead to hypocalcemia. The full Thiazide mnemonic is Hyperglycemia, Hyperlipidemia, Hyperuricemia, and Hypercalcemia (along with hypokalemia and hyponatremia). Reference: Pharmacotherapy of Hypertension.\">C) Hypocalcemia.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Hyperlipidemia (specifically increased LDL and triglycerides) is a known side effect (the 'L' in HyperGLUC).\">D) Hyperlipidemia.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q17 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q17<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Hypertensive Encephalopathy is a severe manifestation of a hypertensive emergency characterized by headache, altered mental status, and seizures. What is the fundamental pathophysiological mechanism driving this condition?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Excessive cerebral vasoconstriction leads to ischemic stroke, not the diffuse cerebral edema seen in encephalopathy.\">A) Excessive cerebral vasoconstriction leading to global brain ischemia.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Hypertensive encephalopathy occurs when systemic blood pressure exceeds the upper limit of cerebral autoregulation (typically when MAP is greater than 150-160 mmHg). The cerebral arterioles lose their ability to constrict and suddenly dilate (autoregulatory failure), leading to cerebral hyperperfusion, breakdown of the blood-brain barrier, endothelial exudation, and widespread cerebral edema (often manifesting as Posterior Reversible Encephalopathy Syndrome - PRES). Reference: Hypertension Primer, AHA.\">B) Failure of cerebral autoregulation leading to massive hyperperfusion and cerebral edema.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Microvascular thrombosis describes TTP or DIC, not the direct hemodynamic effect of hypertensive encephalopathy.\">C) Diffuse microvascular thrombosis causing multiple lacunar infarcts.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Rupture of berry aneurysms causes a subarachnoid hemorrhage, which is a focal catastrophic event, not the diffuse process of encephalopathy.\">D) Rupture of congenital berry aneurysms in the Circle of Willis.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q18 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q18<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Historically, &#8220;Malignant Hypertension&#8221; was defined by severe blood pressure elevation accompanied by specific ophthalmologic findings on fundoscopy. According to the Keith-Wagener-Barker classification, what Grade IV finding specifically defines malignant hypertension?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Arteriolar narrowing is a Grade I change, indicating mild, chronic hypertensive retinopathy.\">A) Mild generalized arteriolar narrowing.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Arteriovenous (AV) nicking is a Grade II change due to thickened arterioles crossing venules.\">B) Arteriovenous (AV) nicking.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Cotton-wool spots and flame hemorrhages define Grade III hypertensive retinopathy (accelerated hypertension).\">C) Cotton-wool spots and flame-shaped hemorrhages.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"By definition, Grade IV hypertensive retinopathy\u2014the hallmark of 'Malignant Hypertension'\u2014requires the presence of Papilledema (swelling of the optic disc). This signifies catastrophic failure of autoregulation and acutely elevated intracranial pressure, representing a true hypertensive emergency requiring immediate hospital admission. Reference: Keith-Wagener-Barker Classification.\">D) Papilledema (optic disc swelling).<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q19 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q19<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Obstructive Sleep Apnea (OSA) is a leading cause of secondary and resistant hypertension. What is the primary pathophysiological mechanism linking intermittent nocturnal hypoxia to sustained systemic hypertension?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Direct renal hypoperfusion is the mechanism for renal artery stenosis, not OSA.\">A) Direct nocturnal hypoperfusion of the juxtaglomerular apparatus leading to massive renin release.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"In Obstructive Sleep Apnea, repeated episodes of airway collapse cause intermittent hypoxia and hypercapnia. These chemical triggers stimulate the carotid body chemoreceptors, triggering a massive, sustained surge in sympathetic nervous system (SNS) activity. This sympathetic overactivity persists even during daytime wakefulness, leading to chronic vasoconstriction and hypertension. Reference: AHA Scientific Statement on Sleep Apnea and Cardiovascular Disease.\">B) Chemoreceptor stimulation triggering a massive, sustained surge in sympathetic nervous system activity.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Aldosterone adenomas cause primary hyperaldosteronism; OSA does not induce adrenal adenomas.\">C) Hypoxia-induced hyperplasia of the adrenal cortex, leading to primary hyperaldosteronism.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"While endothelial dysfunction occurs, structural destruction of the baroreceptors is not the primary driver; baroreceptors actually reset to higher pressures.\">D) Structural destruction of the carotid sinus baroreceptors due to wide swings in intrathoracic pressure.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q20 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q20<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient undergoing solid organ transplantation develops severe de novo hypertension shortly after starting their immunosuppressive regimen. Which of the following drug classes is notoriously responsible for this via profound renal afferent arteriolar vasoconstriction?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Antimetabolites like mycophenolate do not typically cause severe hypertension.\">A) Antimetabolites (e.g., Mycophenolate mofetil).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Calcineurin inhibitors (CNIs), such as Cyclosporine and Tacrolimus, are notorious for causing significant de novo hypertension. Their primary mechanism is inducing intense vasoconstriction of the renal afferent arterioles, which leads to reduced renal blood flow, sodium retention, and activation of the RAAS and sympathetic systems. Calcium channel blockers (like amlodipine) are often the preferred treatment for CNI-induced hypertension. Reference: KDIGO Guidelines for Transplant Recipients.\">B) Calcineurin inhibitors (e.g., Cyclosporine, Tacrolimus).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"mTOR inhibitors can cause hyperlipidemia and proteinuria, but are less commonly associated with severe vasoconstrictive hypertension compared to CNIs.\">C) mTOR inhibitors (e.g., Sirolimus).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Monoclonal antibodies like Basiliximab are generally well-tolerated hemodynamically and do not cause profound renal vasoconstriction.\">D) IL-2 receptor antagonists (e.g., Basiliximab).<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q21 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q21<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          According to the widely adopted 2017 ACC\/AHA High Blood Pressure Guidelines, what blood pressure readings strictly define &#8220;Stage 2 Hypertension&#8221;?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"120-129 \/ less than 80 mmHg is defined as 'Elevated Blood Pressure'.\">A) Systolic 120-129 mmHg AND Diastolic less than 80 mmHg.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"130-139 \/ 80-89 mmHg is defined as 'Stage 1 Hypertension'.\">B) Systolic 130-139 mmHg OR Diastolic 80-89 mmHg.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The 2017 ACC\/AHA guidelines notably lowered the thresholds for hypertension. Stage 2 Hypertension is now defined as a Systolic BP greater than or equal to 140 mmHg OR a Diastolic BP greater than or equal to 90 mmHg. (Stage 1 is 130-139 or 80-89). Reference: 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for High Blood Pressure.\">C) Systolic greater than or equal to 140 mmHg OR Diastolic greater than or equal to 90 mmHg.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Greater than 180\/120 mmHg defines a Hypertensive Crisis (Urgency\/Emergency).\">D) Systolic greater than or equal to 180 mmHg OR Diastolic greater than or equal to 120 mmHg.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q22 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q22<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          When transitioning a hypertensive heart failure patient from an ACE inhibitor (e.g., Lisinopril) to an ARNI (Sacubitril\/Valsartan), a mandatory washout period is required. What is the correct duration and primary clinical rationale for this washout?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"There is no requirement for a 1-week washout to prevent renal failure; the concern is angioedema.\">A) A 7-day washout to prevent acute interstitial nephritis and renal failure.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"A strict 36-hour washout period is mandatory when switching from any ACE inhibitor to Sacubitril\/Valsartan (an ARNI). Both ACE inhibitors and Neprilysin inhibitors (Sacubitril) block the degradation of bradykinin. Concurrent use leads to a massive accumulation of bradykinin, causing a profoundly high risk of life-threatening Angioedema. Notably, no washout is needed when switching from an ARB to an ARNI. Reference: PARADIGM-HF Trial \/ ACC\/AHA HF Guidelines.\">B) A 36-hour washout to prevent life-threatening Angioedema due to overlapping bradykinin accumulation.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Hyperkalemia can happen, but the strict 36-hour rule is specifically FDA-mandated to prevent angioedema.\">C) A 24-hour washout to prevent profound hyperkalemia and lethal arrhythmias.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Zero washout is only acceptable when switching from an ARB to an ARNI. ACEi to ARNI requires 36 hours.\">D) No washout period is required; they can be switched on the same day.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q23 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q23<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Dihydropyridine calcium channel blockers (like Amlodipine) frequently cause dose-dependent peripheral edema. What is the fundamental hemodynamic mechanism of this specific side effect?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Amlodipine does not cause systemic sodium\/water retention; diuretics are actually quite ineffective at treating CCB edema for this reason.\">A) Systemic sodium and water retention at the proximal convoluted tubule.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Amlodipine causes preferential vasodilation of the precapillary arterioles, without corresponding dilation of the postcapillary venules. This mismatch severely increases hydrostatic pressure within the capillary bed, forcing fluid into the interstitium and causing peripheral edema. Adding an ACE inhibitor or ARB (which dilates the postcapillary venules) normalizes the pressure gradient and effectively resolves the edema. Reference: Pathophysiology of CCB-induced edema.\">B) Preferential pre-capillary arteriolar vasodilation increasing local hydrostatic pressure.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"CCBs do not cause lymphatic obstruction.\">C) Direct toxic injury to the lymphatic vessels leading to lymphedema.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Allergic histamine release is an anaphylactic mechanism, not the dose-dependent mechanism of CCB edema.\">D) Allergic histamine release leading to increased capillary permeability.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q24 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q24<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Abrupt discontinuation of which centrally-acting antihypertensive agent is most famous for causing a severe &#8216;rebound hypertension&#8217; crisis due to an acute massive outpouring of catecholamines?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Amlodipine has a very long half-life and does not typically cause acute rebound hypertension.\">A) Amlodipine.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Lisinopril discontinuation causes BP to return to baseline, but rarely causes a catastrophic 'rebound' crisis.\">B) Lisinopril.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Clonidine is a centrally acting alpha-2 adrenergic agonist. Chronic use downregulates sympathetic outflow. Abrupt cessation removes this central inhibition, leading to a massive, sudden surge of catecholamines (norepinephrine). This results in a dangerous hyperadrenergic state (rebound hypertension, tachycardia, sweating) mimicking a pheochromocytoma. It must always be tapered slowly. Reference: Pharmacotherapy of Hypertension.\">C) Clonidine.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Hydrochlorothiazide discontinuation does not cause a sympathetic catecholamine surge.\">D) Hydrochlorothiazide.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q25 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q25<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Isolated Systolic Hypertension (ISH) is the most common form of hypertension in the elderly population (e.g., BP 170\/70 mmHg). What is the primary pathophysiological driver of this specific pattern?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Increased peripheral resistance drives diastolic hypertension, more common in younger adults.\">A) A pathological increase in systemic small-vessel peripheral vascular resistance.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"As patients age, the large elastic arteries (like the aorta) undergo arteriosclerosis\u2014losing elastin, gaining collagen, and becoming stiff. This profound decrease in arterial compliance means the aorta cannot dilate to accommodate the stroke volume during systole, resulting in an enormous spike in systolic pressure. Furthermore, the stiff vessels recoil too quickly, failing to sustain diastolic pressure, leading to a widened pulse pressure. Reference: Pathophysiology of Aging and Hypertension.\">B) Age-related stiffening and decreased compliance of the aorta and large elastic arteries.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Hyperaldosteronism elevates both systolic and diastolic pressures by increasing volume.\">C) Autonomous hypersecretion of aldosterone due to adrenal microadenomas.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"While renal function declines with age, the specific extreme widening of the pulse pressure in ISH is purely a mechanical large-vessel issue.\">D) Age-related loss of nephrons leading to chronic sodium retention and volume overload.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n  <\/div>\n<\/div>\n\n<script>\n  let mcq32Correct = 0;\n  let mcq32Answered = 0;\n  const mcq32Total = 25;\n\n  document.querySelectorAll('#mcq32-quiz-wrapper .quiz-card').forEach(card => {\n    const buttons = card.querySelectorAll('.opt-btn');\n    buttons.forEach(btn => {\n      btn.addEventListener('click', function() {\n        if (card.getAttribute('data-answered') === 'true') return;\n        card.setAttribute('data-answered', 'true');\n        mcq32Answered++;\n\n        document.getElementById('mcq32-answered-count').innerText = mcq32Answered;\n        const pct = (mcq32Answered \/ mcq32Total) * 100;\n        document.getElementById('mcq32-progress-bar').style.width = pct + '%';\n\n        buttons.forEach(b => {\n          b.disabled = true;\n          b.classList.remove('hover:bg-slate-900', 'cursor-pointer');\n          b.classList.add('opacity-50', 'cursor-not-allowed');\n        });\n\n        const isCorrect = this.getAttribute('data-correct') === 'true';\n        const explanation = this.getAttribute('data-explanation');\n\n        if (isCorrect) {\n          mcq32Correct++;\n          document.getElementById('mcq32-correct-count').innerText = mcq32Correct;\n          this.classList.remove('opacity-50', 'border-slate-800', 'bg-slate-950');\n          this.classList.add('bg-teal-950\/80', 'border-teal-500', 'text-teal-200', 'opacity-100', 'border-2');\n          this.innerHTML += ' <span class=\"font-bold\">&#10004; CORRECT!<\/span>';\n        } else {\n          this.classList.remove('opacity-50', 'border-slate-800', 'bg-slate-950');\n          this.classList.add('bg-cyan-950\/80', 'border-blue-500', 'text-cyan-200', 'opacity-100', 'border-2');\n          this.innerHTML += ' <span class=\"font-bold\">&#10006; INCORRECT<\/span>';\n\n          buttons.forEach(b => {\n            if (b.getAttribute('data-correct') === 'true') {\n              b.classList.remove('opacity-50', 'border-slate-800', 'bg-slate-950');\n              b.classList.add('bg-teal-950\/40', 'border-teal-500\/55', 'text-teal-200', 'opacity-100', 'border-2');\n              b.innerHTML += ' <span class=\"font-bold\">&#10004; (Correct)<\/span>';\n            }\n          });\n        }\n\n        const feedback = card.querySelector('.feedback-box');\n        feedback.innerHTML = `\n          <div class=\"font-extrabold uppercase tracking-widest text-xs mb-2 ${isCorrect ? 'text-teal-400' : 'text-cyan-400'}\">\n            ${isCorrect ? 'Clinical Explanation & Reference' : 'Explanation, Correct Answer & Reference'}\n          <\/div>\n          <p class=\"m-0\">${explanation}<\/p>\n        `;\n        feedback.classList.remove('hidden');\n        feedback.classList.add('block', isCorrect ? 'bg-teal-950\/45' : 'bg-cyan-950\/20', 'border-2', 'border-solid', isCorrect ? 'border-teal-500\/30' : 'border-blue-500\/30', 'text-slate-200', 'mt-4');\n      });\n    });\n  });\n<\/script>\n","protected":false},"excerpt":{"rendered":"<p>\u26a1 Advanced Cardiology Series &#8211; Part 32 Interactive Cardiology MCQs #32 Post-Graduate Level Masterclass: Hypertension \ud83e\ude78 Live Scoreboard 0\/ 25 Correct Progress: 0\/25 Q1 The landmark SPRINT trial evaluated intensive versus standard blood pressure control. What was the primary finding regarding the intensive treatment target (systolic BP less than 120 mmHg) in non-diabetic adults at [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":68078,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","nfd_image_url":"","nfd_onboarding_generated":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-68077","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Interactive Cardiology MCQs 32: Hypertension - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-32-hypertension\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Interactive Cardiology MCQs 32: Hypertension - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"\u26a1 Advanced Cardiology Series &#8211; Part 32 Interactive Cardiology MCQs #32 Post-Graduate Level Masterclass: Hypertension \ud83e\ude78 Live Scoreboard 0\/ 25 Correct Progress: 0\/25 Q1 The landmark SPRINT trial evaluated intensive versus standard blood pressure control. What was the primary finding regarding the intensive treatment target (systolic BP less than 120 mmHg) in non-diabetic adults at [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-32-hypertension\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-10T01:21:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-10T01:22:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-32-Hypertension.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1208\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-32-hypertension\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-32-hypertension\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Interactive Cardiology MCQs 32: Hypertension\",\"datePublished\":\"2026-11-10T01:21:56+00:00\",\"dateModified\":\"2026-11-10T01:22:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-32-hypertension\\\/\"},\"wordCount\":1610,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-32-hypertension\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Interactive-Cardiology-MCQs-32-Hypertension.jpg\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-32-hypertension\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-32-hypertension\\\/\",\"name\":\"Interactive Cardiology MCQs 32: Hypertension - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-32-hypertension\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-32-hypertension\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Interactive-Cardiology-MCQs-32-Hypertension.jpg\",\"datePublished\":\"2026-11-10T01:21:56+00:00\",\"dateModified\":\"2026-11-10T01:22:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-32-hypertension\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-32-hypertension\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-32-hypertension\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Interactive-Cardiology-MCQs-32-Hypertension.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Interactive-Cardiology-MCQs-32-Hypertension.jpg\",\"width\":1208,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-32-hypertension\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Interactive Cardiology MCQs 32: Hypertension\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Interactive Cardiology MCQs 32: Hypertension - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-32-hypertension\/","og_locale":"en_US","og_type":"article","og_title":"Interactive Cardiology MCQs 32: Hypertension - All About Cardiovascular System and Disorders","og_description":"\u26a1 Advanced Cardiology Series &#8211; Part 32 Interactive Cardiology MCQs #32 Post-Graduate Level Masterclass: Hypertension \ud83e\ude78 Live Scoreboard 0\/ 25 Correct Progress: 0\/25 Q1 The landmark SPRINT trial evaluated intensive versus standard blood pressure control. What was the primary finding regarding the intensive treatment target (systolic BP less than 120 mmHg) in non-diabetic adults at [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-32-hypertension\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2026-11-10T01:21:56+00:00","article_modified_time":"2026-11-10T01:22:02+00:00","og_image":[{"width":1208,"height":675,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-32-Hypertension.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-32-hypertension\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-32-hypertension\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Interactive Cardiology MCQs 32: Hypertension","datePublished":"2026-11-10T01:21:56+00:00","dateModified":"2026-11-10T01:22:02+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-32-hypertension\/"},"wordCount":1610,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-32-hypertension\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-32-Hypertension.jpg","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-32-hypertension\/","url":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-32-hypertension\/","name":"Interactive Cardiology MCQs 32: Hypertension - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-32-hypertension\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-32-hypertension\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-32-Hypertension.jpg","datePublished":"2026-11-10T01:21:56+00:00","dateModified":"2026-11-10T01:22:02+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-32-hypertension\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-32-hypertension\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-32-hypertension\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-32-Hypertension.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-32-Hypertension.jpg","width":1208,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-32-hypertension\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Interactive Cardiology MCQs 32: Hypertension"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/68077","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=68077"}],"version-history":[{"count":1,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/68077\/revisions"}],"predecessor-version":[{"id":68079,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/68077\/revisions\/68079"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/68078"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=68077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=68077"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=68077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}